摘要
作为不能手术的早期非小细胞肺癌的首选治疗方式，体部立体定向放疗（SBRT）与手术效果不相上下，但数据多来源于非随机对照及回顾性的研究，需要更多病例数的随机前瞻性临床研究来给出有说服力的结论。生物等效剂量〉100Gy的SBRT剂量分割模式局部控制率和生存率更高，小的肿瘤体积局部控制率更高。
As the first treatment of choice for medically inoperable patients with early stage non-small cell lung cancer, it is demonstrated that the therapeutic outcome of stereotactic body radiation therapy （SBRT） is similar to that of surgery, but the data is mainly from nonrandomized controls and retrospective studies. More cases of randomized prospective clinical trials are needed to confirm the conclusions. The biologically effective dose 〉100 Gy is associated with improved local control and overall survival, and the small tumor volume is correlated with higher local control rate.
作者
苏创煌
李德锐
Su Chuanghuang;Li Derui(Department of Radiotherapy, Cancer Hospital of Shantou University Medical College, Shantou 515000, China)
出处
《国际肿瘤学杂志》
CAS
2018年第3期176-179,共4页
Journal of International Oncology
关键词
癌
非小细胞肺
立体定向放疗
Carcinoma
non-small-cell lung
Stereotactic body radiation therapy
